dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

APRINOIA has allowed Celgene to use
its PET tau imaging agent in global
clinical trials

APRINOIA and Celgene partner on promising PET tracer

by John R. Fischer , Staff Reporter
Clinical-stage biotechnology enterprise APRINOIA Therapeutics has given the thumbs-up to Celgene Corporation to make use of its imaging tracer, APN-1607, in global clinical trials.

The Taiwan-based manufacturer will receive annual license and usage fees in exchange for allowing Celgene to use its novel investigational PET agent, which holds the potential for visualizing tau pathology in diverse tauopathies, to support patient selection and efficacy evaluation in its studies.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"We are excited to collaborate with Celgene, one of our most valued global partners," Ming-Kuei Jang, CEO of APRINOIA, said in a statement. "With APN-1607's unique properties, we believe it can offer our partners a valuable tool to validate therapeutic candidates for diverse neurodegenerative disorders, including multiple tauopathies.”

Evaluated clinically in the U.S., Japan, Taiwan and mainland China, APN-1607 holds the potential to visualize tau pathology in diverse tauopathies, such as mild cognitive impairment; dementia due to Alzheimer’s disease; corticobasal degeneration syndrome; and progressive supranuclear palsy (PSP). The FDA recently granted orphan drug designation status to the agent for PSP.

The agent is currently deployed worldwide by APRINOIA at a number of academic medical centers, which are able to apply it to obtain a better understanding of the natural history of tau pathology in rare tauopathies as well as Alzheimer’s.

APRINOIA is also leveraging its use in the company’s tau therapeutic program due to the value it offers in the development of effective treatments for such diseases.

The development of imaging agents for visualizing tau is currently a high priority among many molecular imaging researchers. One team, for instance, recently published their findings on their work in identifying 18F-R0-948 as a promising second-generation PET tracer for imaging and measuring such pathology.

Additionally, Cerveau Technologies announced, this past summer, plans to expand its production network to enhance access and opportunities in research for [18F]MK-6240, a novel contrast agent utilized in PET scans to assess the status and progression of neurofibrillary tangles (NFTs) within the brain as part of several neurodegenerative conditions including Alzheimer’s disease.

“This expansion of the biomarker production network underscores our commitment to the broader scientific research community and our support of the industry’s initiatives to combat neurodegenerative disorders,” Rick Hiatt, president and chief executive officer of Cerveau Technologies, said in a statement at the time.

The specific costs of license and usage fees to APRINOIA were not disclosed.

APRINOIA declined to comment. Celgene did not respond for comment.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED